Novo Nordisk clinical trials are the talk of the medical community as the 2026 European Congress on Obesity (ECO) approaches. From 12–15 May in Istanbul, Turkey, the pharmaceutical giant will unveil data from 52 different abstracts, marking a pivotal moment for the future of metabolic health. This massive data dump aims to clarify how higher doses of semaglutide and new combination therapies like CagriSema can further push the boundaries of weight management.
The focus of these Novo Nordisk clinical trials extends beyond simple weight loss; the research dives into cardiovascular health, physical function, and the specific needs of women navigating the complexities of menopause.
High-Dose Wegovy® and Oral Innovation
Central to the presentation is the STEP UP trial, which examines a 7.2 mg dose of semaglutide. For patients who plateau on standard dosages, these Novo Nordisk clinical trials suggest that a higher ceiling may provide the necessary metabolic nudge to achieve sustained, long-term results.
Wegovy® (Semaglutide) Pipeline & Real-World Data
| Trial / Study | Dosage | Key Analysis Point | Presentation Timing |
| STEP UP | Semaglutide 7.2 mg | Body Weight Loss & Menopausal Status | Tuesday, 12 May |
| OASIS 4 | Oral Semaglutide 25 mg | Physical Function Improvements | Poster Session |
| ORION | Oral Semaglutide | Comparison vs. Orforglipron | Friday, 15 May |
| SELECT | Semaglutide 2.4 mg | MACE in Menopausal Women | Tuesday, 12 May |
Learn More: Novo Nordisk Announces Significant Price Reduction on Wegovy & Ozempic
Amgen Data Breach: Biotechnology Giant Discloses Theft of Patient Health Data in Cloud Cyberattack
Amgen data breach headlines have put the biotechnology giant at the center of the healthcare industry's escalating cybersecurity crisis. Amgen Inc. disclosed on July 31, […]
Novo Nordisk Ziltivekimab ZEUS Trial: Phase 3 Cardiovascular Readout Misses Primary MACE Reduction Target
Novo Nordisk has released headline results from the Phase 3 ZEUS cardiovascular outcomes trial evaluating monthly subcutaneous ziltivekimab in patients with ASCVD, CKD, and elevated […]
Roche Biocon Perjeta Lawsuit: Genentech Sues Over Biocon’s Breast-Cancer Biosimilar in New Jersey Court
Genentech and Roche have filed a new patent-infringement lawsuit against Biocon in New Jersey federal court, alleging Biocon's proposed pertuzumab biosimilar infringes patents covering Perjeta, […]
Next-Generation Therapy: The Impact of CagriSema
The scientific leadership of the company is most evident in the results of the REDEFINE program. These Novo Nordisk clinical trials evaluate CagriSema, a combination of semaglutide and the long-acting amylin analogue, cagrilintide. By targeting multiple satiety pathways simultaneously, CagriSema represents the “next-gen” of obesity treatment.
The scientific leadership of the company is most evident in the results of the REDEFINE program. These Novo Nordisk clinical trials evaluate CagriSema, a combination of semaglutide and the long-acting amylin analogue, cagrilintide. By targeting multiple satiety pathways simultaneously, CagriSema represents the “next-gen” of obesity treatment.
